Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 11 - Drugs for disorders of the respiratory system
Patents for A61P 11 - Drugs for disorders of the respiratory system (87,767)
06/2003
06/18/2003CN1424026A Ambroxol hydrochloride containing hydroxypropyl beta-cyclodextrin and its preparation
06/18/2003CN1111529C Piperazino derivatives as neurokinin antagonists
06/18/2003CN1111528C Piperazino derivatives as neurokinin antagonists
06/17/2003US6579982 Treating inflammation, cancer
06/17/2003US6579970 Specific octapeptides, antibodies that recognize and bind to these compounds, polynucleotides that encode these compounds and immune effector cells raised in response to presentation of these epitopes.
06/17/2003US6579896 Method for treating allergies using substituted pyrazoles
06/17/2003US6579874 Substituted azoles
06/17/2003US6579872 Bezamide derivatives for the treatment of diseases mediated by cytokines
06/17/2003US6579863 Nitrosated and nitrosylated compounds and compositions and their use for treating respiratory disorders
06/17/2003US6579861 Administering alpha -hydroxy-2-methylene-19-nor-homopregnacalciferol for therapy of psoriasis
06/17/2003US6579700 Neuropeptide Y (NPY); isolated peptide of given amino acid sequence; may be useful in regulating central and peripheral nervous and endocrine systems
06/14/2003CA2412464A1 Dextromethorphan tannate
06/12/2003WO2003048181A1 17.alpha. -cyclic esters of 16-methylpregnan-3,20-dione as anti-inflammatory agents
06/12/2003WO2003048180A1 Crystalline form of a ribofuranosyluronamide derivative; a human adenosine a2a receptor agonist
06/12/2003WO2003048162A1 Novel crystalline compound
06/12/2003WO2003048160A1 Ring fused pyrazole derivatives
06/12/2003WO2003048153A1 Process for the preparation of compositions having an increased amount of pharmaceutically active salts of rotamers
06/12/2003WO2003048129A1 Substituted 4-phenyltetrahydroisoquinolines, method for the production thereof, the use thereof as medicaments, in addition to a medicament containing same
06/12/2003WO2003048125A1 Aminotetralin derivatives as muscarinic receptor antagonists
06/12/2003WO2003048124A1 4-piperidinyl alkylamine derivatives as muscarinic receptor antagonists
06/12/2003WO2003048123A1 Substituted 2-amino-cycloalkanecarboxamides and their use as cysteine protease inhibitors
06/12/2003WO2003048122A2 Inhibitors of cytosolic phospholipase a2
06/12/2003WO2003048120A2 2-aryl pyrrologpyrimidines for a1 and a3 receptors
06/12/2003WO2003047628A1 Combination of an adenosine a2a receptor agonist and an adrenergic beta-2 receptor agonist
06/12/2003WO2003047598A1 Pharmaceutical combinations of adenosine a-2a and beta-2-adrenergic receptor agonists
06/12/2003WO2003047597A1 Combination of crystalline form of a ribofuranosyluronamide derivative and tiotropium salt
06/12/2003WO2003047591A1 Remedies for primary pulmonary hypertension
06/12/2003WO2003047588A1 Kit for reducing aching caused by pde-v inhibitors
06/12/2003WO2003047578A1 Combination of a selective pde4 inhibitor and an adrenergic beta-2 receptor agonist
06/12/2003WO2003047570A1 Benzazole derivatives for the treatment of scleroderma
06/12/2003WO2003047561A1 Use of 4-oxobutanoic acid derivatives in the treatment of inflammation
06/12/2003WO2003047554A1 Transdermal drug delivery system of strychnine, brucine, securinine and their salts
06/12/2003WO2001088126A8 REGULATION OF HUMAN α1Α ADRENERGIC RECEPTOR-LIKE G PROTEIN-COUPLED RECEPTOR
06/12/2003WO2001085096A9 Mast cell regulation
06/12/2003US20030109683 Hybrid proteins; controlling gene expression in gene therapy; Parkinson's disease
06/12/2003US20030109578 Treating acute and chronical inflammatory processes in a patent in need thereof which comprises administering to such patent an amount effective therefor of a compound or salt thereof according to claim 1.
06/12/2003US20030109570 Activate a peroxisome proliferator-activated receptor (PPAR) alpha or gamma which is an intranuclear transcription factor. The compound may be used as an active ingredient to give a drug for preventing or treating a variety of diseases
06/12/2003US20030109564 Treating: allergy, allergy-induced airway responses, congestion, hypotension, cardiovascular disease, hypotension, diseases of the GI tract, hyper and hypo motility and acidic secretion of the gastrointestinal tract, obesity, sleep
06/12/2003US20030109556 Melanocortin receptor ligands
06/12/2003US20030109551 A therapeutic or preventive agent for pulmonary insufficiency, containing as an active ingredient a diaminotrifluoromethylpyridine derivative represented by the formula (I) or its salt: anti-inflammatory agent or an anti-
06/12/2003US20030109540 Pharmaceutical dosage forms comprising descarboethoxyloratadine
06/12/2003US20030109539 Treating a condition selected from the group consisting of anxiety, depression, substance abuse, neuropathic pain, acute pain, migraine, asthma, cough and improved cognition, in a subject in need thereof comprising administering a compound
06/12/2003US20030109538 Pyrmidine derivatives as selective inhibitors of cox-2
06/12/2003US20030109533 New benzenesulphonamide compounds
06/12/2003US20030109527 Novel hydroxy diphenylurea sulfonamides, compositions and intermediates thereof. The hydroxy
06/12/2003US20030109524 Benzocycloalkylenylamine derivatives as muscarinic receptor antagonists
06/12/2003US20030109510 Pharmaceutical formulations comprising a combination of (R,R)-formoterol and budesonide and the use of such formulations in medicine, particularly in the prophylaxis and treatment of respiratory diseases
06/12/2003US20030109497 Novel imidazolidine derivatives, their preparation and their use
06/12/2003US20030109491 Use of heparinoid derivatives for the treatment and diagnosis of disorders which can be treated with heparinoids
06/12/2003US20030109480 Inhibitors of endothelin-1 synthesis
06/12/2003US20030109452 Containing phenylalanine, leucine, alanine, and lysine residues are disclosed. The peptides can be used in antibacterial, antifungal, anticancer, and other biological applications.
06/12/2003US20030109436 Wherein cysteine residue number 132 or 135 is replaced by another amino acid residue, preferably an alanine or serine residue and/or wherein the leucine residue at position 193 is the carboxy terminal residue. DNA sequence codes for cells
06/12/2003US20030109429 Methods for the production of purified recombinant human uteroglobin for the treatment of inflammatory and fibrotic conditions
06/12/2003US20030109426 Cyclosporins for the treatment of respiratory diseases
06/12/2003US20030108544 Compositions and methods for the diagnosis and treatment of tumor
06/12/2003US20030107149 Thin film with non-self-aggregating uniform heterogeneity and drug delivery systems made therefrom
06/12/2003CA2469385A1 Substituted 4-phenyltetrahydroisoquinolines, process for their preparation, their use as medicament, and medicament containing them
06/12/2003CA2469085A1 Pharmaceutical combinations of adenosine a-2a and beta-2-adrenergic receptor agonists
06/12/2003CA2468927A1 Ring fused pyrazole derivatives
06/12/2003CA2468676A1 Combination of a selective pde4 inhibitor and an adrenergic beta-2 receptor agonist
06/12/2003CA2468525A1 Process for the preparation of compositions having an increased amount of pharmaceutically active salts of rotamers of 4-[4-[(1r)-[4-(trifluoromethyl)phenyl]-2-methoxyethyl]-(3s)-methyl-1-piperazinyl]-4-methyl-1-[(4,6-dimethyl-5-pyrimidinyl)carbonyl]
06/12/2003CA2467435A1 Substituted 2-amino-cycloalkanecarboxamides and their use as cysteine protease inhibitors
06/11/2003EP1318150A1 Novel crystals of 1,3,4-oxadiazole derivative, process for producing the crystals and medicines containing the same as the active ingredient
06/11/2003EP1318149A1 Amidine derivatives, their preparation and application as medicines and pharmaceutical compositions containing them
06/11/2003EP1318147A1 Novel pyrimidine derivative and novel pyridine derivative
06/11/2003EP1317930A1 Antithrombin for prevention and therapy of vascular proliferative diseases
06/11/2003EP1317924A1 Kit for reducing aching caused by pde-v inhibitors
06/11/2003EP1317555A1 Rat cathepsin, dipeptidyl peptidase i (dppi): crystal structure, inhibitors and its uses
06/11/2003EP1317532A2 Novel human gene relating to respiratory diseases, obesity, and inflammatory bowel disease
06/11/2003EP1317531A2 Isolated human phosphatase proteins, nucleic acid molecules encoding them, and uses thereof
06/11/2003EP1317465A1 Purine derivatives
06/11/2003EP1317458A2 Interphenylene 7-oxabicyclic[2.2.1]heptane oxazoles as prostaglandin f2alpha antagonists
06/11/2003EP1317457A2 INTERHETEROARYL 7-OXABICYCLIC 2.2.1]HEPTANE OXAZOLES AS PROSTAGLANDIN F 2$g(a)? ANTAGONISTS
06/11/2003EP1317454A2 Caspase inhibitors and uses thereof
06/11/2003EP1317453A1 Isoxazoles and their use as inhibitors of erk
06/11/2003EP1317452A1 Pyrazole compounds useful as protein kinase inhibitors
06/11/2003EP1317450A1 Pyrazole compounds useful as protein kinase inhibitors
06/11/2003EP1317449A1 Pyrazole compounds useful as protein kinase inhibitors
06/11/2003EP1317448A1 Pyrazole compounds useful as protein kinase inhibitors
06/11/2003EP1317447A1 Pyrazole compounds useful as protein kinase inhibitors
06/11/2003EP1317444A1 Pyrazole compounds useful as protein kinase inhibitors
06/11/2003EP1317443A2 Chemokine receptor binding heterocyclic compounds
06/11/2003EP1317428A1 Pyrrolidine-2-carboxylic acid hydrazide derivatives for use as metalloprotease inhibitors
06/11/2003EP1317421A1 2-amino-2-alkyl-5 heptenoic and heptynoic acid derivatives useful as nitric oxide synthase inhibitors
06/11/2003EP1317420A1 2-amino-2-alkyl-3 hexenoic and hexynoic acid derivatives useful as nitric oxide synthase inhibitors
06/11/2003EP1317417A2 2-amino-2-alkyl-3 heptenoic and heptynoic acid derivatives useful as nitric oxide synthase inhibitors
06/11/2003EP1317280A2 Vaccine against streptococcus pneumoniae
06/11/2003EP1317279A2 Vaccine against streptococcus pneumoniae
06/11/2003EP1317259A2 Prevention of acute sinusitis and sinus attack
06/11/2003EP1317252A2 Pharmaceutical composition having specific water activity
06/11/2003EP1267976A4 Microencapsulated fragrances and methods of coating microcapsules
06/11/2003EP1133307B1 Use of a composition comprising soy protein, dietary fibres and a phytoestrogen compound in the prevention and/or treatment of pulmonary diseases
06/11/2003EP0750511B1 Treating inflammation via the administration of specific sulfatase enzymes and/or sulfation inhibitor
06/11/2003CN1423695A Antisense oligonucleotides
06/11/2003CN1423646A Hetero cyclo-alkylsulfonyl pyrazole derivatives as anti-inflammatory/analgesic agents
06/11/2003CN1423645A 维他命d类似物 Vitamin d analogues
06/11/2003CN1423641A Quaternary salts of N-substituted cyclic or acyclic amines as pharmaceuticals
06/11/2003CN1423638A Ox (adi) azolyl-hydroxamic acids useful as procollagen C-proteinase inhibitors
06/11/2003CN1423633A Azetidine derivatives, preparation thereof and pharmaceutical compositions
06/11/2003CN1423630A Quaternary ammonium compounds and their use as anti-tussive agents
1 ... 596 597 598 599 600 601 602 603 604 605 606 607 608 609 610 611 612 613 614 615 616 ... 878